Clinical Trials Sponsored by OM Pharma SA

Total 69 results

OM Pharma SA

Terminated

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Atopic Dermatitis

Germany, France, Poland, Netherlands
OM Pharma SA

Recruiting

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

Respiratory Tract Infections | Wheezing Lower Respiratory Illness

United Kingdom, Hungary, Poland, Switzerland, Germany, Italy
OM Pharma SA
Parexel

Recruiting

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

Recurrent Wheezing | Wheezing Lower Respiratory Illness

United States
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
Hervé SPECHBACH
OM Pharma SA

Completed

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. (COVID-19)

COVID-19 Virus Disease

Switzerland
Rose Pharma SA

Recruiting

An Open, Non-comparative, Single-centre Post Marketing Clinical Followup (PMCF) Investigation to Evaluate Performance and Safety of the ALIAXIN Fillers Used as Intended

Esthetics

Italy
Medesis Pharma SA

Recruiting

Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease (NanoLi®_AD)

Alzheimer's Disease

France
Medesis Pharma SA

Terminated

NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

COVID-19 Pandemic

Brazil
Labatec Pharma SA

Unknown

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Osteoporosis, Postmenopausal

Switzerland
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
UCB Pharma SA

Completed

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Narcolepsy With Cataplexy

Belgium
UCB Pharma SA

Completed

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Epilepsy

United States, France, Germany, Spain, United Kingdom
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Epilepsy

Ukraine, Belgium, Germany, Hong Kong, India, South Africa, Taiwan, Sweden, Korea, Republic of, Singapore, Russian Federation, Austria, Italy, Norway, Czechia
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (NexT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic

Poland, Sweden, Hungary, Czechia
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain
UCB Pharma SA

Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Epilepsy | Partial Seizures

China
UCB Pharma SA

Completed

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Epilepsy

France, United States, Mexico, Turkey, Belgium, Germany
UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
UCB Pharma SA
Parexel

Completed

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Romania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
UCB Pharma SA
Parexel

Completed

A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects

Healthy Subjects

China
UCB Pharma SA
Parexel

Completed

An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE)

Rheumatoid Arthritis

China
Therabel Pharma SA/NV

Completed

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR)

Atherosclerosis | Stable Angina Pectoris

Belgium
UCB Pharma SA, Belgium
Parexel

Completed

A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C)

Rheumatoid Arthritis

China
Sankom SA
InterMedService SA; Pharmaxi LLC

Unknown

Study to Evaluate Impact SANKOM Patent Socks in Patients With CVI

Chronic Venous Insufficiency

Ukraine
Therabel Pharma SA/NV
ECSOR

Unknown

Prevention of Antibiotic-Associated Diarrhoea With Prolardii (PAADI)

Antibiotic-associated Diarrhea

Belgium
Vifor Pharma
Socar Research SA

Terminated

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure (EFFICACY-HF)

Chronic Heart Failure | Iron Deficiency Anemia | Iron Deficiency | Anaemia

France, Netherlands, Denmark, Germany, Israel
University Hospital, Ghent
UCB Pharma SA

Completed

Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis (SCINTRA)

Rheumatoid Arthritis | Axial and Peripheral Spondyloarthritis

Belgium
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
UCB Pharma SA
ReSearch Pharmaceutical Services, Inc.

Completed

Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (SONAR-12)

Rheumatoid Arthritis

Spain
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Epilepsy | Partial Onset Seizures

China, Japan
Farma de Colombia SA

Completed

Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

Hypertension

Colombia, Ecuador
University Hospital, Geneva
Bayer; AstraZeneca; Vifor Pharma; Labatec Pharma SA

Terminated

Improving Knowledge in Heart Failure Inpatient With Therapeutic Education (EDUC-IC)

Medication Adherence | Knowledge, Attitudes, Practice | Heart Failure With Reduced Ejection Fraction | Pharmacist-Patient Relations | Heart Failure; With Decompensation

Switzerland
Chang Gung Memorial Hospital
Scientis Pharma SA

Recruiting

Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation

Hyperpigmentation; Postinflammatory

Taiwan
Celon Pharma SA
National Center for Research and Development, Poland

Recruiting

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Sarcoma | Gastric Cancer | Cholangiocarcinoma | Bladder Cancer | Endometrial Cancer | Squamous Non-small Cell Lung Cancer | Other Solid Tumours

Poland
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

Healthy

Poland
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

Healthy Volunteers

Poland
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

Bipolar Depression

Poland

3

Subscribe